CALCIUM CITRATE MALATE WITH D (calcium citrate malate/cholecalciferol (vitamin D3))
CALCIUM · VITAMIN D DEFICIENCY ·+5
NAT'L VIT. CO.
Drug class
Vitamin D
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis. Read more about Vitamin D
307 drugs in this class 101 manufacturers
Drugs in Vitamin D
COD LIVER OIL (ascorbic acid/cod liver oil)
VITAMIN A · VITAMIN C DEFICIENCY
MASON DISTRIB.
MAXIMUM D3 (cholecalciferol (vitamin D3))
VITAMIN D · HYPOPARATHYROIDISM ·+6
PRO-PHARMA LLC
CALCIUM CARBONATE/VITAMIN D3 (calcium carbonate/cholecalciferol (vitamin D3))
CALCIUM · VITAMIN D DEFICIENCY ·+5
21ST CENTURY HE
CALCIUM (calcium carbonate/cholecalciferol (vit D3)/vit K1)
CALCIUM · VITAMIN D DEFICIENCY ·+5
Walgreen Co
OYSTER SHELL-D (calcium carbonate/cholecalciferol (vitamin D3))
CALCIUM · VITAMIN D DEFICIENCY ·+5
PLUS PHARMA,INC
CALCIDOL (ergocalciferol (vitamin D2))
VITAMIN D · HYPOPARATHYROIDISM ·+9
PATRIN PHARMA
PRO-CAL (calcium phosphat/magnesium hydroxide/vit C/vit D3/phosphorus)
CALCIUM · VITAMIN D DEFICIENCY ·+5
PRO-BIOTIKS
HEARTBURN & ACID REFLUX (calcium no.1/vit D3/pyridoxine/folic acid/vit B12/aloe vera)
CALCIUM · VITAMIN DEFICIENCY ·+3
MASON DISTRIB.
Filter & compare in the drug finder →
Opens the drug finder with Vitamin D preselected. Add indication or manufacturer filters there.
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis.
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling.
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease.
-
fda.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis
-
fda.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling Clinically, these agents a...
-
cancer.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis
-
nih.gov
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney d...
-
nih.gov
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling
-
fda.gov
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease
-
fda.gov
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.